Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing

Inflammation Research

Volumn 46, Issue 6, 1997, Pages 211-215

  DiMartino, M ^a   Wolff, C ^a   High, W ^a   Stroup, G ^a   Hoffman, S ^a   Laydon, J ^a   Lee, J C ^a   Bertolini, D ^b   Galloway, W A ^c   Crimmin, M J ^c   Davis, M ^c   Davies, S ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BAYER AG   (Germany)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Arthritis; Metalloproteinases; TNF

Indexed keywords

ALLYL N1 HYDROXYLISOBUTYL N4 (METHYLCARBAMOYL 2 PHENYLETHYL)SUCCINAMIDE; ANTIRHEUMATIC AGENT; BB 1101; BB 1433; ENDOTOXIN; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N4 (2 CYCLOHEXYLMETHYLCARBAMOYLETHYL) N1 DIHYDROXYISOBUTYLSUCCINAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BLOOD LEVEL; BONE DEFECT; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PLETHYSMOGRAPHY; RADIOGRAPHY; RAT; TARSAL BONE; TIBIA;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DEXAMETHASONE; DRUG COMBINATIONS; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; PENTOXIFYLLINE; PROTEASE INHIBITORS; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8544258841     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050175     Document Type: Article

References (15)

1. Birkedal-Hansen H, Moores WGI, Bodden MK, Windsor LJ, et al. Matrix Metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197-250.
2. Gearing AJH, Beckett P, Christodoulou M, Churchill M, et al. Processing of tumour necrosis factor-precursor by metalloproteinases. Nature 1994;370:555-7.
3. McGeehan GM, Becherer JD, Bast RC, Boyer CM, et al. Regulation of tumour necrosis factor- processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
4. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-20.
5. Brennan FM, Maini RN, Feldmann M. TNF - A pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
6. DiMartino MJ, High W, Galloway WA, Crimmin MJ. Preclinical antiarthritic activity of matrix metalloproteniase inhibitors. Ann NY Acad Sci 1994;732:411-3.
7. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. Cancer Res 1993;53:2087-91.
8. 14C] acetylated collagen. Anal Biochem 1979;99:340-5.
9. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit hone inhibitor of collagenase. Biochem J 1981;195:159-65.
10. Sellers A, Reynolds JJ, Meilkle MC. Neutral metalloproteinases of rabbit bone. Separation in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochem J 1978;171:493-6.
11. DiMartino M, Slivjak M, Esser K, Wolff C, et al. Adjuvant arthritic (AA) rats exhibit enhanced endotoxin-induced plasma TNF (EIPT) levels. Agents Actions 1993;39:C58-60.
12. Conway JG, Wakefield JA, Brown RH, Marron BE, et al. Inhibition of cartilage and bone degradation in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995;182:449-57.
13. Moreland LW, Margolies GR, Heck LW, Saway PA, et al. Soluble tumor necrosis factor receptor (sTNFR): results of a phase I dose-escalation study in patients with rheumatoid arthritis. Arthr Rheum 1994;37:S295.
14. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
15. Elliot MJ, Maini RN, Feldmann M, Kalden JR, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.